Meta-Nitro Benzaldehyde Pharma Grade API (model MNB-PH-GMP) is a crystalline aromatic aldehyde supplied for oral solid dosage and injectable formulation development. The compound has IUPAC name 3-nitrobenzaldehyde, CAS RN 99-61-6, molecular formula C7H5NO3, and molecular weight 151.12 g/mol. It is a pale-yellow to yellow crystalline powder with a melting range of 56–58 °C and limited aqueous solubility; the combination of a polar aldehyde carbonyl and an aromatic nitro substituent produces a low-melting, static-prone solid that requires closed handling and controlled drying. The product is released under a specification compiled in accordance with ICH Q6A for non-pharmacopoeial materials, with residual solvents controlled per ICH Q3C, elemental impurities per ICH Q3D, and microbial quality aligned with Ph. Eur. 5.1.4 for non-sterile APIs. Batches are supplied with a certificate of analysis that includes actual mill lot, recrystallisation solvent, sieve fraction, and retest date.

Unlike technical-grade material, the pharma-grade product is recrystallised from ethanol or isopropanol, dried under vacuum at 40 °C, and sieved through a 40-mesh (425 μm) screen before packaging. Technical lots may contain para-nitrobenzaldehyde or aldehyde oxidation products at levels above 1.0%, which alters the impurity profile and may affect downstream dosage-form stability. The meta substitution pattern is significant because it influences melting point, solubility, and aldehyde reactivity relative to the ortho and para isomers. These differences are not cosmetic; they determine whether a given tablet, capsule, granule, or injectable process can be validated without excessive sticking, capping, or residual solvent failure.

Residual Solvent and Elemental Impurity Control Points

Release and retest control for the pharma-grade product is anchored to the route of administration. Because the same crystallisation and drying train can serve both oral and injectable grades, the stricter parenteral limit is assigned whenever a lot is intended for dual use. Residual solvents are measured by headspace gas chromatography per USP <467>; Class 1 solvents are controlled at ICH Q3C limits and Class 3 solvents are kept at or below 0.5% for any individual solvent. Elemental impurities are determined by ICP-MS per USP <233> and assessed against ICH Q3D oral and parenteral permitted daily exposure values. Water content is measured by Karl Fischer titration per USP <921>; values above 0.5% trigger vacuum drying at 40 ± 2 °C before processing.

Because the material is not a harmonised pharmacopoeial monograph item, specification justification follows ICH Q6A decision tree #2 for specified impurities and degradation products. Each batch is also tested for residual ethanol or isopropanol; if the value exceeds 0.5%, the batch is returned to the vacuum dryer until the result is below the release limit. A batch record review includes differential scanning calorimetry thermogram comparison, sieve analysis, and bulk density, because variability in crystal habit affects tableting and capsule filling even when chemical purity is acceptable.

What Limits Direct Compression for This Low-Melting Crystalline Solid?

Direct compression is generally unsuitable for meta-nitrobenzaldehyde as a sole API in tablets because the melting onset of 56–58 °C and plate-like crystal habit produce poor flow, low bulk density, and die-wall sticking. On a rotary tablet press equipped with 12 stations and run at 40 rpm, unlubricated material may exhibit hopper arching and weight variation above 5%; a preblend with 0.5% w/w colloidal silicon dioxide and 1.0% w/w pregelatinised starch reduces flow defects but does not fully eliminate capping at compression pressures above 150 MPa. Wet granulation is therefore preferred for tablet dosage forms. A 5% w/w povidone K30 binder solution in ethanol-water 70:30 v/v is added in a high-shear granulator; end point is controlled by chopper motor torque and granule size analysis, with target wet mass median diameter below 600 μm.

Drying is the critical step. Because the melting onset is close to common tray-dryer inlet settings, inlet air should be set at 40 °C and bed depth kept below 2 cm. Deeper beds on static tray dryers have shown caking and local softening, particularly when the granule moisture exceeds 2.0% w/w entering the dryer. Dried granules are milled through a 1.0 mm screen at low speed, with the mill temperature monitored and maintained below 35 °C. Final granule moisture for compression is specified at 1.0–2.0% w/w; material below 0.8% w/w moisture may be brittle and may increase capping risk.

In high-shear granulation, the addition rate of the povidone binder is controlled at 10–15 g/min per kg of dry blend to avoid local overwetting. The chopper speed is set at 1500 rpm for 2–3 minutes after binder addition; longer wet massing can generate heat from viscous dissipation and raise the granule bed temperature toward the softening range. The 56–58 °C melting onset is not a bulk melting failure point under these conditions, but local hot spots in the chopper zone can cause smearing on the bowl wall. Bowl wall temperature is monitored with contact probes, and the batch is discharged when the product temperature reaches 28–30 °C.

For capsule filling, the material is generally incorporated into a roller-compacted granulation rather than filled directly as powder. Direct powder filling can produce unacceptable fill weight variability on dosator machines because the API has low bulk density; tamping pin stations may densify the powder but cause build-up on pins. Roller compaction at roll pressure 3–5 MPa with a 1.0 mm screen yields granules of 0.25–0.50 g/cm³ bulk density and improves encapsulation on a dosator or tamping-style machine. The granulation is blended with lactose monohydrate or microcrystalline cellulose and magnesium stearate at 0.5% w/w; lubricant blend times are kept below 5 min to avoid over-lubrication and delayed dissolution. For granules, high-shear wet granulation is preferred over fluidised-bed granulation when the formulation contains the API above 20% w/w because the low melting point can cause defluidisation and lumping in the fluidised bed if inlet air exceeds 45 °C.

Moisture determination in granules containing meta-nitrobenzaldehyde should not use a standard loss-on-drying oven at 105 °C because the API melts below that temperature and may partially volatilise or degrade. A vacuum oven at 40 °C or Karl Fischer titration on a methanol suspension is more appropriate. This method substitution is necessary for granule moisture limits of 1.0–2.0% w/w to be reliable release data.

When Low Aqueous Solubility and Low Melting Onset Constrain Injectable Formulation

Injectable formulation work with meta-nitrobenzaldehyde begins with solubility screening rather than direct dissolution into water. The intrinsic aqueous solubility is low; published data for the specific co-solvent or cyclodextrin configuration is limited, so a preformulation screen across water, ethanol, propylene glycol, PEG 400, and 2-hydroxypropyl-β-cyclodextrin is required to determine whether a target concentration of ≥ 1 mg/mL can be achieved with physiologically acceptable pH. If a solution is obtained, it is filtered through a 0.22 μm sterilising-grade membrane within an ISO 14644-1 Class 5 environment; the dry API itself is not sterile and cannot be terminally sterilised as a dry solid because temperatures required for depyrogenation exceed the melting range.

Injectable-grade lots are controlled for bacterial endotoxins at ≤ 0.25 EU/mg and for sub-visible particle burden after filtration. The final product must comply with sterility per USP <71>, bacterial endotoxins per USP <85>, particulate matter per USP <788>, and cGMP requirements under 21 CFR 211.94, 211.165, and 211.167. Because the aldehyde group can react with primary amine-containing buffers such as tromethamine or amino acids, the formulation should avoid amino buffers unless reaction kinetics have been characterised. The degradation products from aldehyde-amine reactions may be coloured and can exceed the 0.10% unspecified impurity threshold during accelerated stability studies.

pH adjustment alone is not sufficient to ionise the molecule because the nitro and aldehyde groups are not readily protonated or deprotonated over the range used for parenteral products. Therefore, the solubility screen must include non-ionising co-solvents or a complexing agent. Sulfite-based antioxidants such as sodium metabisulfite are generally incompatible with the aldehyde group because bisulfite addition across the carbonyl can form a sulfonate adduct and reduce assay. Nitrogen sparging and non-nucleophilic antioxidants such as butylated hydroxyanisole or edetate disodium may be evaluated, but compatibility must be confirmed by HPLC. This incompatibility is a key difference from neutral APIs that do not contain a free aldehyde.

Direct comparison with the ortho and para isomers is necessary because all three materials may be present as impurities in synthesis streams. Ortho-nitrobenzaldehyde has a melting range of 42–44 °C, making it more prone to milling and drying sticking than the meta isomer. Para-nitrobenzaldehyde has a melting range above 103 °C, which is more thermally robust, but its lower solubility in ethanol and isopropanol changes recrystallisation and cleaning behaviour. The meta isomer is compatible with Class 3 solvent recrystallisation and can be dried below 40 °C, but it cannot be subjected to hot-melt extrusion above 50 °C without softening. These differences are summarised in Table 2.

Particle size distribution is controlled because it affects dissolution and powder flow. The sieve cut is typically not less than 90% through 425 μm and not more than 50% through 75 μm unless a micronised grade is requested. Micronisation for injectable or low-dose solid oral formulations may increase surface area but also increases electrostatic charging and aldehyde oxidation; micronised lots require nitrogen blanketing and cold storage below 8 °C unless stability data support otherwise.

Stability of the neat API is typically assigned after storage at 25 °C and 60% RH in the intended packaging. Because the aldehyde is susceptible to oxidation, open-container stability is shorter than closed-container stability. Stress testing under oxidative, thermal, and photolytic conditions follows ICH Q1A and ICH Q1B; the main degradation indicator is total related substances and appearance change. If a lot is to be used for injectable dosage forms, additional testing at 4 °C and 25 °C in final solution is necessary because aldehyde degradation in aqueous co-solvent systems may differ from the solid state.

Pharma-grade lots are packaged in double polyethylene-lined fibre drums under nitrogen, with desiccant if storage is expected above 60% RH. The material should be stored in a cool, dry, light-resistant area; repeated opening without nitrogen purge may cause aldehyde oxidation and an increase in related substances. Cleaning validation on stainless steel and polytetrafluoroethylene surfaces uses swab sampling and HPLC analysis at 254 nm; acceptance limits are based on health-based exposure limits. Because the meta isomer is less water-soluble than some common neutral APIs, an aqueous-only cleaning procedure may leave visible residue on flat surfaces; heated 70% ethanol or isopropanol is used before final aqueous rinse. Equipment used for tablet, capsule, granule, or injectable processing should be dedicated or cleaned with a validated cycle, and the next product should be selected to avoid primary amine-containing compounds that could form Schiff-base residues if the cleaning cycle fails.